Recent News
Mercury-Containing Dental Amalgam May Have Harmful Health Effects to High-Risk Groups
On September 24th, 2020, the FDA published a press release issuing updated recommendations regarding the potential risks of mercury-containing dental amalgam fillings to high-risk groups. The FDA is issuing these updates as a response to certain risks surrounding the dental fillings that may predominantly impact certain high-risk groups. Dental Amalgam is a Substance Used…
FDA News Release: Opdivo and Yervoy Combination Approved to Treat Mesothelioma
For the first time in 16 years, a drug combination and FDA-approved systemic therapy has been approved to treat malignant pleural mesothelioma that cannot be removed surgically. The first-line treatment for adults will include drug combination therapy using Opdivo (nivolumab) and Yervoy (ipilimumab) to increase the chances of patient survival. Here, the pharmaceutical liability attorneys…
Recent FDA News Release: Benzodiazepines Boxed Warning to Be Updated to Include Serious Risks
On September 23rd, the U.S. Food and Drug Administration (FDA) announced that it would be requiring “class-wide labeling changes” for psychoactive drugs that fall under the class of Benzodiazepines. The label change to the Boxed Warning will include benzos’ risks of abuse, dependence, misuse, addiction and potential withdrawal symptoms. The labeling update is a reaction…
Bladder Drug Manufacturers Face Lawsuits Over Retinal Damage Linked to Elmiron
On Wednesday, August 12th, women in two separate complaints filed suit against units of Johnson & Johnson, Bayer and Teva Pharmaceuticals USA Inc. after they developed eye damage after taking bladder medication Elmiron. Here, the pharmaceutical liability attorneys at Peter Angelos P.C. discuss the latest updates in Elmiron litigation and what it means for patients…
Elmiron Update: Warnings Changed to Include Risk of Eye Damage
On June 16th, 2020, the Food and Drug Administration (FDA) announced labeling changes to Elmiron, a popular anticoagulant that is commonly prescribed to treat bladder pain caused by interstitial cystitis and osteoarthritis. Here, the pharmaceutical liability attorneys at Peter Angelos P.C. discuss the potential dangers to consumers taking Elmiron, and how to seek legal representation…
Elmiron Linked to Vision Loss
Elmiron is a popular anticoagulant that is commonly prescribed to treat bladder pain caused by interstitial cystitis and osteoarthritis. Recently, Elmiron has been linked to the increased risk of pigmentary maculopathy and other forms of vision loss and damage. The pharmaceutical liability attorneys at Peter Angelos P.C. Law are actively investigating cases regarding the use…
FDA Requests Removal of Zantac From the Market Immediately
On April 1st, the Food and Drug Administration (FDA) announced its request for all prescription and over-the-counter ranitidine drugs to be removed from the market immediately. This decision was made based on an ongoing investigation of possible carcinogenic effects of the contaminant N-nitrosodimethylamine, or NDMA. Here, the pharmaceutical liability attorneys at Peter Angelos, P.C. discuss…
Zantac Manufacturer Recalls Medication Due to Confirmed Contamination
Sandoz Inc. has voluntarily recalled the generic version of common medication Zantac after the medication was confirmed to be contaminated with a human carcinogen. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the updates to the ongoing Zantac claims. Global health regulators recently raised concerns about the possibility that the…
Carcinogen Found in Stomach Drug Leads to Halt in Distribution
Global health regulators have raised the alarm about the possibility that the widely used drug, Zantac, could be tainted with the same cancer-causing agent found in Valsartan earlier this year. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos detail the preliminary results of the FDA and EU probes. Officials are Investigating…
Updates on Link Between Flesh-Eating Genital Infection and Diabetes Drug SGLT2 Inhibitors
A recent study investigated a potential link between a Type-2 diabetes drug and a severe and potentially fatal necrotizing fasciitis called Fournier gangrene. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the recent study and how SGLT2 inhibitors may potentially be linked to the development of Fournier gangrene. The First…